Expert Cancer Panel: Newly diagnosed stage IV lung adenocarcinoma, EGFR mutation positive

12 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Recorded on 3/13/2021

95-year-old women, former smoker (3 pack years) with newly diagnosed stage IV lung adenocarcinoma, EGFR mutation positive, cT4NxM1c

Summary:
- In the setting of brain metastases and known EGFR+ mutation in this 95 year old patient, the decision to pursue initial treatment with a TKI like osimertinib versus radiotherapy would be dependent on the overall burden of disease and the type of mutation.
- Osimertinib is preferred as a first line approach over radiotherapy, particularly whole brain radiation, to reduce morbidity, especially if the mutation is ALK positive as it responds dramatically to TKIs.
- The panel recommends starting osimertinib at the highest dose the patient may tolerate to treat the brain metastases, although eventually dose adjustment is recommended given the patient’s age and functional status as a known side effect is fatigue.
- In the setting of no underlying cardiomyopathy, an echocardiogram is not necessary prior to starting osimertinib.
Repeat imaging should be performed at 6 weeks after starting a TKI to assess for disease response.
- Concurrent chemotherapy is not recommended with osimertinib or other TKIs; if there is disease progression on this therapy, consolidative radiotherapy with SRS is the next step.


At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.

Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.

Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca

Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
Category
Oncology
Be the first to comment

Up Next